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To determine clinical characteristics of patients hospitalized in the United Kingdom with pandemic (H1N1) 
2009, we studied 1,520 patients in 75 National Health Service hospitals. We characterized patients who 
acquired influenza nosocomially during the pandemic (H1N1) 2009 outbreak. Of 30 patients, 12 (80%) of 
15 adults and 14 (93%) of 15 children had serious underlying illnesses. Only 12 (57%) of 21 patients who 
received antiviral therapy did so within 48 hours after symptom onset, but 53% needed escalated care or 
mechanical ventilation; 8 (27%) of 30 died. Despite national guidelines and standardized infection control 
procedures, nosocomial transmission remains a problem when influenza is prevalent. Health care 
workers should be routinely offered influenza vaccine, and vaccination should be prioritized for all patients 
at high risk. Staff should remain alert to the possibility of influenza in patients with complex clinical 
problems and be ready to institute antiviral therapy while awaiting diagnosis during influenza outbreaks. 
Nosocomial influenza is a well-recognized problem in acute-care hospital settings (1,2). 
Outbreaks of influenza A have been reported in general wards (3,4), pediatric units (5),  neonatal 
intensive care units (ICUs) (6–8), hemopoietic and solid organ transplantation units (9–11), 
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oncology and neurology units (12,13), and facilities for the elderly and for long-term care (14–
17). Associated illness and death rates are particularly high in immunocompromised patients 
(18–20). 
On June 11, 2009, the World Health Organization reported the first influenza pandemic 
of the 21st century (21,22). Although most cases of pandemic (H1N1) 2009 have been mild or 
subclinical, patients with severe disease have considerably affected hospital systems (23). Three 
nosocomial outbreaks of pandemic (H1N1) 2009 were reported in hemopoietic transplantation 
units and oncology wards. One outbreak was reportedly mild (24), and the other 2 involved 
aggressive illness, severe complications, and deaths (25,26). 
In addition to outbreaks of nosocomial influenza, sporadic nosocomial influenza 
infections also occur but generally are not reported in the literature. We describe the clinical and 
epidemiologic characteristics of nosocomial pandemic (H1N1) 2009 infections during 2009–
2010 in the United Kingdom that were identified during surveillance rather than through 
outbreak control activity. 
Methods 
During the pandemic (H1N1) 2009 outbreak in the United Kingdom, the Influenza 
Clinical Information Network (FLU-CIN) collected clinical and epidemiologic data for patients 
with virologically confirmed pandemic (H1N1) 2009 virus infection admitted to hospitals (27). 
Data included demography, symptoms, medical history, influenza vaccination history, relevant 
timelines, investigations and results, treatment (e.g., antiviral and antibacterial drugs), outcome, 
and cause of death when available. Trained health care workers abstracted data from case notes. 
During May 11, 2009–January 31, 2010, data were accrued from 75 National Health Service 
hospitals in 31 cities or towns in England, Scotland, Wales, and Northern Ireland. 
From this source cohort, we defined patients with nosocomial pandemic (H1N1) 2009 as 
those admitted to a hospital for a reason other than acute respiratory infection in whom 
respiratory symptoms developed >72 hours (3 days) after admission. In addition, we included 
infants who had not left the hospital since birth in whom pandemic (H1N1) 2009 had developed. 
We included transfers from other hospitals when a transfer was for a reason other than influenza 
and when the history of influenza clearly indicated that it had been acquired at another hospital. 
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FLU-CIN procedures were reviewed and approved by the Ethics and Confidentiality Committee 
of the National Information Governance Board for Health and Social Care in England for 
collection, storage, and use of personal data for surveillance purposes. 
Results 
Of 1,520 patients in the FLU-CIN cohort, illnesses in 30 (2.0%) (15 children) met the 
criteria for nosocomial influenza (Tables 1, 2 [adults] and Tables 3, 4 [children]). Patient ages 
ranged from 41 days to 76 years at onset of influenza symptoms (median age 44 years for adults 
and 1 year for children). 
Concurrent Conditions and Reasons for Admission 
Twelve (80%) adults and 14 (93%) children had serious underlying illnesses. The most 
common illnesses were hematologic malignancy for adults (5), and congenital abnormality or 
prematurity (7) or malignancy (4) for children. 
Of the 15 adults, 2 had been admitted for elective surgical procedures; 1 for emergency 
surgery; and 8 for deterioration of chronic conditions, including complications caused by 
chemotherapy, malignancy, or transplantation. Two patients were admitted for pancreatitis (1 of 
whom had underlying myeloma); 1 patient was admitted for obstetric complications, and another 
patient was admitted for psoriasis. Of 15 children, 3 were admitted for elective procedures, 6 had 
been in the hospital since birth (because of prematurity or congenital abnormality), 1 was 
transferred from another hospital, and 5 had acute conditions (Table 2). 
Pandemic Vaccination Status and Use of Antiviral and Antibacterial Drugs 
None of the patients had received pandemic influenza vaccine. Although 14 adults were 
eligible because of concurrent conditions, influenza symptoms developed in 11 either before 
vaccine became available or before they would have seroconverted if vaccinated at the earliest 
opportunity (vaccine became available in the United Kingdom at the end of October 2009). Four 
children were eligible because of age and concurrent conditions, and symptoms developed in 3 
before vaccine became available or before they would have seroconverted Only 2 patients (both 
adults) had received seasonal influenza vaccine. 
Twenty-one (72%) of 29 patients (10 children) received antiviral medication as inpatients 
(data were unknown for 1 patient); all initially received oseltamivir as monotherapy. Therapy for 
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1 patient (no. 18) was switched to zanamivir after 10 days of oseltamivir therapy because drug-
resistant virus carrying the H275Y mutation was identified. Administration of antiviral drugs 
ranged from 0 to 8 days after symptom onset; 12 (57%) of 21 patients who received therapy did 
so within 48 hours. Sixteen patients were already receiving antibacterial drugs when influenza 
symptoms began. Two of these patients had a bacterial co-infection: coagulase-negative 
staphylococci in a blood culture for 1 patient and Pseudomonas aeruginosa in an unspecified 
intravenous line in 1 patient. Twelve patients received antibacterial drugs during their respiratory 
illness, 2 of whom had Haemophilus influenzae in sputum samples and 1 (co-infected with 
rhinovirus) who had had a blood culture positive for Klebsiella sp. 
Signs and Symptoms 
The most common signs were fever (8 [53%] adults and 12 [80%] children), cough (10, 
mostly adults), coryza (8, mostly children), and dyspnea (7). Fewer patients had malaise (4); 
myalgia (3); anorexia, nausea, diarrhea (2 each); and arthralgia, sore throat, headache, vomiting, 
altered consciousness, sneezing, and rash (a child) (1 each). 
Course of Illness 
Median length of hospitalization before onset of influenza symptoms was 11 days for 
adults (range 4–78 days) and 13 days (range 6–54 days) for children, excluding infants in a 
hospital since birth. For infants in a hospital since birth, the interval from birth to onset of 
influenza signs ranged from 41 to 123 days (median = 78 days). 
Results of chest radiography ≤3 days after onset of influenza symptoms were documented 
for 8 adults and 5 children (43%). Of these patients, 4 adults and 1 child (38%) had 
radiologically confirmed pneumonia. 
Level 0 is care given to patients whose care needs can be met through normal ward care. 
Level 1 care is given to patients at risk for a deteriorating condition or recently relocated from 
higher levels of care whose needs can be met in an acute-care ward with additional advice and 
support from the critical-care team. Level 2 care is given to patients requiring more detailed 
observation or intervention, including support for a single failing organ system and those 
changing from higher levels of care (high dependency unit). Level 3 care is given to patients 
requiring advanced respiratory support alone or basic respiratory support and support for >2 
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organ systems. This level includes all patients with complex conditions requiring support for 
multiorgan failure (ICU). 
Seven adults and 8 children (50%) required level 3 care (ICU, pediatric ICU, or neonatal 
ICU). One (3%) adult required level 2 care. Six adults required mechanical ventilation and 1 
required noninvasive ventilation (data for ventilatory support were unknown for 1 adult). Three 
children required mechanical ventilation and 1 required noninvasive ventilation. The remaining 4 
children who received level 3 care were 3 infants and 1 child, each of whom required a period of 
close monitoring, but did not ultimately require ventilation. The remaining 7 adults and 7 
children required level 0 or 1 care. 
Outcomes and Mortality Rates 
Five (33%) of 15 adults died in the acute-care hospital that provided treatment, 2 within 
30 days of symptom onset. Of adults who died, 3 had underlying malignancy (1 noted to be 
terminal) or were immunocompromised and 2 had diabetes (type I and type II respectively). 
Pandemic (H1N1) 2009 was included in the recorded causes of death for all 5 adults. Although 
some patients had a prolonged hospital stay of <7 months, all remaining adults recovered from 
influenza and were discharged from the hospital. 
Of 15 children, 3 (20%) were known to have died, although only 1 (a neonate with 
multiple congenital problems) died at the hospital where surveillance was conducted; acute 
respiratory distress syndrome/lower respiratory tract infection was stated as a cause of death. 
Another child, with malignancy, whose death was expected, died at home shortly after discharge. 
The third child was transferred to another hospital, and cause of death is unknown. All other 
children recovered from pandemic (H1N1) 2009. Two children remained in the hospital for 
treatment of their underlying malignancy, and the other children were discharged. 
Discussion 
Although pandemic (H1N1) 2009 produced a generally mild illness, in the United 
Kingdom, as elsewhere, severe illness developed in a small proportion of relatively young 
patients who required hospitalization (28). Although nosocomial outbreaks of pandemic (H1N1) 
2009 have been described, (24–26) sporadic nosocomial cases of pandemic (H1N1) 2009 
identified during surveillance activities have not been described. The present case series has the 
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advantage of being derived from a larger cohort of hospital inpatients in whom confirmation of 
pandemic (H1N1) 2009 was obtained by using nationally standardized PCR criteria, from 
settings where clinical management and infection control precautions were driven by national 
guidelines (29,30), and with data abstracted by trained nurses (27). 
We based our definition of nosocomial influenza on a recent study of health care–
associated influenza in children (31). A recent systematic review of incubation periods of acute 
respiratory viral infections found that the median incubation period for influenza was 1.4 days 
for influenza A, and symptoms developed in 95% of patients in <2.8 days (32). These findings 
suggest that our cutoff point, 3 days after admission, make inclusion of community cases 
unlikely. In addition, in no patients did onset of respiratory illness occur <4 days after hospital 
admission; median length of hospitalization before symptom onset was 11 days for adults and 13 
days for infants. Therefore, inadvertent inclusion of community-acquired cases is highly 
unlikely. 
On the basis of information obtained in the study, we cannot determine where and from 
whom patients acquired influenza. However, 3 routes are possible. First, infection could have 
been acquired from other patients; 1 patient shared a bay with a patient who was presymptomatic 
at the time but for whom influenza was diagnosed 1 day later. Second, transmission from visitors 
of patients cannot be ruled out. Although national guidelines strongly discourage persons with 
influenza-like symptoms from visiting patients (29), this recommendation may have been 
difficult to implement, particularly for parents of sick children who often provide most hands-on 
care in a hospital. Third, transmission may have occurred from an infectious health care worker 
(because staff continue to work when infected with influenza [33]) or from contaminated hands 
of a health care worker. Transmission from asymptomatic persons might occur in all 3 instances 
(34). 
Nosocomial cases in this study occurred equally in adults and children. Consistent with 
previous findings (3), most patients had >1 serious underlying illnesses, notably hematologic 
malignancies, congenital disorders, or prematurity. Staff and caregivers of patients with 
hematologic malignancy and prematurity are often particularly vigilant for symptoms suggestive 
of infectious disease. Although we detected nosocomial influenza in patients admitted to 
nonmedical areas (for emergency or elective surgery), many cases of nosocomial infection in 
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other patient groups probably have been overlooked, particularly because influenza in these 
groups is likely to have been milder. Additionally, some patients are likely to have been 
discharged from a hospital during the incubation period of nosocomially acquired pandemic 
influenza. Thus, in this case series, detecting such patients would not have been possible. 
More than half of patients required level 2 or level 3 care, which is higher than that 
required by the source cohort (12%) (27). Approximately one fifth of children and one third of 
adults died. Although the deaths of 2 patients were expected because of the stage of their 
underlying malignancy, this case-fatality rate is far higher than that for patients with pandemic 
(H1N1) 2009 and concurrent conditions in the source cohort (5%) (27). The combined factors of 
increased host susceptibility (18–20), prolonged virus shedding in immunocompromised children 
(35), and increased likelihood of development of drug resistance (36) raise questions about the 
need for enhanced infection control procedures in special-care infant units, pediatric wards, and 
hemopoietic transplant units and a requirement that staff working in these areas be vaccinated 
(37–39). Precautions should include restricting unnecessary movement of patients to units with 
particularly vulnerable patients and postponement of semi-elective (nonurgent) procedures for 
hematology patients during peak pandemic activity. 
Vaccine against pandemic (H1N1) 2009 became available at the end of October 2009. 
Assuming a 2-week period for vaccine administration, case-patients in groups at risk with 
influenza onset dates after November 30, 2009, could have been vaccinated and would have had 
time to seroconvert (14 days). Using these criteria, we determined that 4 cases (in 3 adults and 1 
child) (13%) were potentially preventable by vaccination; 2 of these patients required escalated 
care and 1 patient died. Although 72% of patients received antiviral therapy, similar to 75% in 
the source cohort (27), we observed avoidable delays between recording of respiratory symptoms 
and start of specific antiviral therapy in some adults and all children. Although under ordinary 
circumstances, the complex clinical picture of such patients might result in delayed or incidental 
finding of influenza, in a pandemic situation or during a seasonal epidemic, clinicians should be 
alert to the possibility of influenza. Delays encountered in this series most likely reflect a failure 
to consider such a diagnosis early. Other reasons are caution or uncertainty in using oseltamivir 
in patients younger than the drug licensing permits (12 months) in nonpandemic situations, 
reluctance to empirically instigate antiviral treatment in advance of a confirmed diagnosis of 
pandemic (H1N1) 2009, lack of confidence about absorption of oseltamivir by nasogastric tube 
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insertion in patients already receiving mechanical ventilation or concerns about potential 
gastrointestinal side effects. 
Nosocomial infections with pandemic (H1N1) 2009 in this case series were associated 
with high rates of illness and death. This finding highlights the need for adherence to infection 
control guidelines for staff and visitors (including the need to urge visitors not to visit when they 
are ill, particularly when providing hands-on care for vulnerable children), staff vaccination, 
maintenance of clinical suspicion for influenza in areas of high risk, prompt (empirical) antiviral 
treatment for vulnerable patients in whom influenza is possible or likely, and consideration of 
postponing nonurgent procedures for hematology patients during periods of known high 
influenza activity. This report demonstrates that nosocomial transmission is a recurrent problem 
when the prevalence of influenza is high and the total effect of nosocomial influenza is 
underestimated by outbreak reports alone. 
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Table 1. Characteristics of 15 hospitalized adults with nosocomial pandemic (H1N1) 2009, United Kingdom, 2009–2010 
Patient no. Age, y/sex Reason for admission Main underlying illnesses Signs and symptoms 
1 51/F Pancreatitis None recorded Fever, unknown data in other fields 
2 44/M Transplant complications Lymphoma Productive cough, headache, coryza, 
myalgia 
3 34/M Emergency surgery Diabetes Unknown 
4 18/F Elective surgery Neurodegenerative disease Dyspnea, malaise 
5 48/M Chemotherapy Hematologic malignancy Fever, sore throat 
6 43/M Pancreatitis Chronic liver disease Fever, malaise, myalgia 
7 51/M Not recorded Lymphoma Fever, dry cough, diarrhea, myalgia, 
arthralgia 
8 39/F Metastatic soft tissue Malignancy Dry cough, dyspnea 
9 76/M Elective surgery Diabetes, heart disease Productive cough, diarrhea, dyspnea 
10 45/F Not stated Myeloma Fever, productive cough, nausea, anorexia, 
malaise 
11 44/F Psoriasis Psoriasis Fever, unknown data in other fields 
12 22/M Posttransplant complications Renal transplant, congenital 
abnormalities 
Fever, cough, anorexia, malaise 
13 52/M Elective procedure Lymphocytic leukemia Dyspnea, altered consciousness 
14 33/F Obstetric complications None recorded Fever, productive cough 





Table 2. Timelines and outcomes for 15 hospitalized adults with nosocomial pandemic (H1N1) 2009, United Kingdom, 2009–2010 
Patient no. Age, y/sex 
Duration, d 
Maximum level 
of care* Outcome† 
Hospital admission to 
symptom onset 
Symptom onset to receipt 
of antiviral therapy 
1 51/F 26 0 0/1 Unknown data 
2 44/M 14 0 0/1 Recovered 
3 34/M 8 0 3 Died 
4 18/F 4 Not given 2 Transferred to other hospital 
5 48/M 9 4 0/1 Recovered 
6 43/M 5 0 0/1 Recovered 
7 51/M 29 0 3 Died 
8 39/F 5 3 0/1 Died 
9 76/M 11 Not given 3 Died 
10 45/F 24 2 0/1 Recovered 
11 44/F 14 Not given 3 Transferred, improved 
12 22/M 5 0 3 Died 
13 52/M 78 1‡ 3 Recovered 
14 33/F 7 3 0/1 Recovered 
15 60/M 13 Not given 3 Recovered 
*Level 0 care is given to patients whose care needs can be met through normal ward care. Level 1 care is given to patients at risk for a deteriorating 
condition or recently relocated from higher levels of care whose needs can be met in an acute-care ward with additional advice and support from the 
critical-care team. Level 3 care is given to patients requiring advanced respiratory support alone or basic respiratory support and support for >2 organ 
systems; this level includes all patients with complex conditions that required support for multiorgan failure (intensive care unit). Level 2 care is given to 
patients requiring more detailed observation or intervention, including support for a single failing organ system and those changing from higher levels of 
care (high dependency unit). 
†Deaths were attributed to pandemic (H1N1) 2009. 
‡Oseltamivir was replaced with zanamivir on day 5 because of identification of the H275Y drug-resistance mutation.  
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Table 3. Characteristics of 15 hospitalized children with nosocomial pandemic (H1N1) 2009, United Kingdom, 2009–2010 
Patient no.  Age/sex Reason for admission Main underlying illnesses Signs and symptoms 
16 12 y/F Elective surgery Heart disease Fever, unknown data in other 
fields 
17 2 y/M Malignancy Malignancy Dry cough, coryza 
18 4 y/F Bone marrow aspirate Acute myeloid leukemia Fever, productive cough 
19 15 y/M Ulcerative colitis Ulcerative colitis Fever, unknown data in other 
fields 
20 123 d/F Inpatient care from birth Prematurity Fever, dyspnea 
21 1 y/F Laryngomalacia, transfer from 
tertiary care center 
Genetic disorder Fever, dyspnea 
22 1 y/M Investigation Acute lymphoblastic leukemia Fever, dry cough, coryza 
23 9 y/M Sepsis Cerebral palsy, septic pressure sore Fever, patient sedated and 
ventilated 
24 12 y/M Anorexia Anorexia Fever, coryza, nausea, 
sneezing 
25 82 d/M Inpatient care from birth Congenital abnormalities Coryza, dyspnoea 
26 64 d/M Inpatient care from birth Congenital abnormalities Fever, coryza 
27 151 d/M Prematurity Prematurity Fever, coryza 
28 101 d/F Inpatient care from birth Congenital abnormalities Fever, coryza 
29 41 d/F Inpatient care from birth Cystic fibrosis Fever, rash 





Table 4. Timelines and outcome for 15 hospitalized children with nosocomial pandemic (H1N1) 2009, United Kingdom, 2009–2010 
Patient no.  Age/sex 
Duration, d 
Maximum level 
of care* Outcome 
Hospital admission to 
symptom onset 
Symptom onset to receipt 
of antiviral therapy 
16 12 y/F 10 Not given 3 Recovered 
17 2 y/M 24 Not given 0/1 Died at home 
18 4 y/F 54 2† 0/1 Recovered 
19 15 y/M 11 8 0/1 Recovered 
20 123 d/F 123‡ Unknown data 3 Died after transfer to another 
hospital 
21 1 y/F 14 1 0/1 Recovered 
22 1 y/M 6 5 3 Recovered 
23 9 y/M Unknown (transferred) 3 3 Recovered 
24 12 y/M 14 Not given 0/1 Recovered 
25 82 d/M 82‡ 1 3 Died§ 
26 64 d/M 64‡ Not given 1 Recovered 
27 151 d/M 151‡ 3 3 Recovered 
28 101 d/F 101‡ 1 3 Recovered 
29 41 d/F 41‡ 1 3 Recovered 
30 9 y/F 12 1 0/1 Recovered 
*Level 3 care is given to patients requiring advanced respiratory support alone or basic respiratory support and support for >2 organ systems; this level inclu
all patients with complex conditions that required support for multiorgan failure (intensive care unit). Level 0 care is given to patients whose care needs can 
through normal ward care. Level 1 care is given to patients at risk for a deteriorating condition or recently relocated from higher levels of care whose needs 
met in an acute-care ward with additional advice and support from the critical-care team. 
†Oseltamivir was replaced with zanamivir on day 11 because of identification of the H275Y drug-resistant mutation (patient also received acyclovir througho
hospitalization); 
‡Inpatient since birth.  
§Attributed to pandemic (H1N1) 2009. 
 
